Illumina Inc
Research Illumina Inc (ILMN) on Bullrun: valuation model: 16.8% overvalued, market cap USD 33.97B, P/E 41.9. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerILMN
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencyUSD
- Valuation signal16.8% overvalued
- Market capUSD 33.97B
- P/E41.9
- Financial periodQ1 2026
- RevenueUSD 1.09B
- Net incomeUSD 134.00M
- Free cash flowUSD 251.00M
- Gross margin66.1%
Valuation Snapshot
Bullrun's latest valuation model marks Illumina Inc as 16.8% overvalued; latest market cap is USD 33.97B; P/E is 41.9.
Peer valuation comparison
Latest P/E is 41.93x versus a Healthcare sector median of 24.46x (71.4% above).
Latest P/E is 41.93x versus a United States median of 24.87x (68.6% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 4.34B | USD 850.00M | USD 931.00M | 66.1% | 5.45 | USD 1.42B | USD 2.55B | USD 2.72B |
| FY2024 | USD 4.37B | -USD 1.22B | USD 709.00M | 65.4% | -7.69 | USD 1.13B | USD 2.62B | USD 2.37B |
| FY2023 | USD 4.50B | -USD 1.16B | USD 283.00M | 60.9% | -7.34 | USD 1.05B | USD 2.26B | USD 5.75B |
| FY2022 | USD 4.53B | USD 762.00M | USD 337.00M | 69.7% | 5.04 | USD 1.23B | USD 0 | USD 10.74B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 33.97B | 41.9 | n/a | n/a |
| 2025 | 2025-12-31 | USD 20.07B | 24.0 | n/a | n/a |
| 2024 | 2024-12-31 | USD 21.25B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 21.51B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 30.94B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 57.84B | 73.4 | n/a | n/a |
About Illumina Inc
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity;
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Illumina Inc overvalued or undervalued?
Bullrun's valuation model currently marks Illumina Inc as 16.8% overvalued.
What is Illumina Inc's market cap?
Illumina Inc's market capitalization is USD 33.97B.
What is Illumina Inc's P/E ratio?
Illumina Inc's price-to-earnings (P/E) ratio is 41.9.
What does Illumina Inc do?
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.